0

“Beehind the Buzz” Show: Featuring Q BioMed Inc. (OTCQB: QBIO) CEO Denis Corin

Q BioMed Inc. (OTCQB: QBIO) aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry-leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. […]

0

“Buzz on the Street” Show: Q BioMed Inc. (OTCQB: QBIO) Partner Mannin Announces USD 7.5M Grant

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony. Mannin is a research-stage biotechnology company focused on the discovery, development, and commercialization of therapeutics for vascular diseases. It was founded in July 2012 and is led […]

0

“Buzz on the Street” Show: Q BioMed Inc. (OTCQB: QBIO) Partnership with Jubilant Radiopharma

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89 Chloride Injection USP (Strontium-89)/Metastron™, with Jubilant Radiopharma for the United States market. Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, […]

0

“Buzz on the Street” Show: Q BioMed Inc. (OTCQB: QBIO) Announces FDA Approval

Q BioMed Inc. (OTCQB: QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company’s FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP. Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets […]

0

“Buzz on the Street” Show: Q BioMed (OTCQB: QBIO) Mannin Research Reports Data: Acute Kidney Injury

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is announcing today that its technology research partner Mannin Research Inc. (Mannin) presented positive data on a potential new treatment for acute kidney injury (AKI). The data was presented at the American Society for Nephrology 2019 Annual Meeting held in Washington DC. Q BioMed Inc. […]